NSCLC Archives -

Transforming NSCLC standards of care

2nd NSCLC Drug Development Summit

https://pharmaphorum.com/events/2nd-nsclc-drug-development-summit/

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

News/ News/ Oncology

Scotland is world’s first country to greenlight Tagrisso for NSCLC

Joy Persaud Astra Zeneca, lung cancer, NSCLC, Tagrisso 0 Comment

Scotland has given the green light to AstraZeneca’s Tagrisso for restricted use to treat adult patients with non-small

Scotland is world’s first country to greenlight Tagrisso for NSCLC

https://pharmaphorum.com/news/scotland-is-worlds-first-country-to-greenlight-tagrisso-for-nsclc/

News/ News/ Oncology

Roche scores adjuvant lung cancer approval for Tecentriq

Phil Taylor adjuvant, immuno-oncology, Keytruda, lung cancer, Merck & Co, NSCLC, Oncology, regulatory approval, Roche, Tecentriq 0 Comment

Roche has claimed an earlier-than-expected FDA approval for its checkpoint inhibitor Tecentriq in non-small cell lung cancer (NSCLC),

Roche scores adjuvant lung cancer approval for Tecentriq

https://pharmaphorum.com/news/roche-scores-early-adjuvant-lung-cancer-approval-for-tecentriq/

News/ News/ Oncology

ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda

Phil Taylor immuno-oncology, Keytruda, Libtayo, Merck & Co, NSCLC, Oncology, Regeneron, Sanofi 0 Comment

There’s no shortage of cancer immunotherapies trying to knock Merck & Co’s Keytruda off the top of the

ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda

https://pharmaphorum.com/news/esmo21-libtayo-extends-survival-in-first-line-nsclc-challenging-keytruda/

Market Access/ News/ News

Takeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approval

Phil Taylor EGFR, Exkivity, fda, NSCLC, Oncology, regulatory approval, Takeda, targeted oncology 0 Comment

Takeda has had a run of bad luck with its Wave1 pipeline of new drug candidates of late,

Takeda gets a win for its Wave1 pipeline, as Exkivity nabs FDA approval

https://pharmaphorum.com/news/takeda-gets-a-win-for-its-wave1-pipeline-as-exkivity-nabs-fda-approval/

Market Access/ News/ News

Merck’s targeted lung cancer drug tepotinib wins early access in UK

Phil Taylor Early Access to Medicines Scheme, Merck KGaA, MHRA, NSCLC, Tabrecta, Tepmetko, UK 0 Comment

The UK drugs regulator has backed Merck KGaA’s MET inhibitor for the treatment of some patients with non-small

Merck’s targeted lung cancer drug tepotinib wins early access in UK

https://pharmaphorum.com/news/mercks-targeted-lung-cancer-drug-tepotinib-wins-early-access-in-uk/

News/ News/ Oncology

Amgen nabs speedy approval for first-ever KRAS drug sotorasib

Phil Taylor Amgen, fda, KRAS, lung cancer, Mirati, NSCLC, Oncology 0 Comment

After decades of mostly unsuccessful R&D, Amgen has claimed the first ever regulatory approval for a drug that

Amgen nabs speedy approval for first-ever KRAS drug sotorasib

https://pharmaphorum.com/news/amgen-nabs-speedy-approval-for-first-ever-kras-drug-sotorasib/

Janssen J&J Johnson and Johnson pharmaceutical companies

News/ News/ Oncology

Janssen claims FDA okay for would-be Tagrisso rival Rybrevant

Phil Taylor Janssen, Johnson & Johnson, lung cancer, NSCLC, Oncology, Rybrevant, targeted oncology 0 Comment

Johnson & Johnson’s Janssen division has claimed a first approval in the US for its bispecific antibody Rybrevant

Janssen claims FDA okay for would-be Tagrisso rival Rybrevant

https://pharmaphorum.com/news/janssen-claims-swift-fda-okay-for-precision-cancer-drug-rybrevant/

News/ News/ R&D/ Top stories

Tagrisso trial halted early after ‘overwhelming’ efficacy

George Underwood AstraZeneca, lung cancer, NSCLC, Tagrisso 0 Comment

A phase III trial for AstraZeneca’s lung cancer drug Tagrisso (osimertinib) will be unblinded early after strong results.

Tagrisso trial halted early after ‘overwhelming’ efficacy

https://pharmaphorum.com/news/tagrisso-trial-halted-early-after-overwhelming-efficacy/

Trending

NSCLC

Login